Vivos Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsVivos Inc. is a radiation oncology medical device company developing Y-90 based precision radionuclide therapies for human and veterinary use.
What they do
Vivos Inc. develops and markets yttrium-90 (Y-90) based precision radionuclide therapy devices, including RadioGel for human solid tumors and positive surgical margins, and IsoPet for veterinary solid tumors. The company also sells PLGA-g-PEG polymers and PrecisionGel, a hydrogel polymer platform for drug delivery. IsoPet has been commercially available since July 2019, while RadioGel is in clinical development for human use.
Revenue drivers
- IsoPet (Animal Division) — Commercial sales of IsoPet for treating solid tumors in companion animals began in July 2019 and represent the primary source of revenue to date.
- PLGA-g-PEG polymers and PrecisionGel — The company also sells these polymer products, which are used for delivering active pharmaceutical ingredients and therapeutic agents, contributing to overall revenue.
Recent performance
Annual revenue rose from $27,995 in 2024 to $68,379 in 2025, though the company remains unprofitable with a net loss of $3.1M in 2025. Quarterly revenue increased from $1,879 in Q3 2025 to $24,752 in Q4 2025, then to $36,068 in Q1 2026 and $36,400 in Q2 2026. Operating cash flow was negative $2.1M in 2025, and the latest balance sheet (June 30, 2026) shows total assets of $2.9M and shareholder equity of $2.8M.
Strategy
The company is advancing its human therapy program, having received FDA approval of an Early Feasibility IDE in July 2026 for a first-in-human study at Mayo Clinic. It is also pursuing expanded regulatory clearances in India through the Drugs Controller General of India and has established a wholly owned subsidiary, Vivos Scientific India LLP, to support manufacturing and clinical initiatives. Internally, the company restructured in January 2025 to align resources with animal and human therapy applications.
Risks
- Regulatory approval for human therapy — RadioGel is not yet approved for human use and requires successful completion of clinical trials and FDA approval, which may not occur.
- Limited revenue base — Revenue is minimal ($68,379 in 2025) and the company has not achieved profitability, raising going-concern risks.
- Dependence on veterinary market — Current commercial sales are limited to IsoPet for animals, a niche market with uncertain growth.
- Cash burn and funding needs — Operating cash flow is negative and the company may need to raise additional capital to fund development and operations.
Outlook
Management anticipates near-term profits, if any, from direct sales of RadioGel (as IsoPet). The company expects to advance its human clinical program with the IDE study at Mayo Clinic and continues to develop international operations in India. No specific revenue or profitability guidance is provided.